Table 1: Classification of ICI.
|
Target |
Molecule |
Indication |
Administration |
|
CTLA4 |
Ipilimumab |
Melanoma RCC NSCLC HCC CRC (MSI-H) |
Intravenous, 1 infusion every 3 weeks, 4 injections total |
|
CTLA4 |
Tremelimumab |
Melanoma Mesothelioma |
Intravenous, 1 infusion every 3 weeks |
|
PD1 |
Nivolumab |
Melanoma NSCLC SCLC RCC LH Squamous Head & Neck cancer Urothelial cancer HCC CRC (MSI-H) Esophageal Squamous cell cancer Mesothelioma TNBC |
Intravenous, 1 infusion every 2 or 4 weeks |
|
PD1 |
Pembrolizumab |
Melanoma NSCLC SCLC LH Primari mediastinal Large B-cell lymphoma Head & Neck Squamous Cell Carcinoma Urothelial cancer Esophageal cancer Gastric cancer CRC (MSI-H) HCC Merkel cell carcinoma Cervical cancer Endometrial cancer RCC Cutaneous squamous cell carcinoma |
Intravenous, 1 infusion every 3 weeks |
|
PD1 |
Cemiplimab |
Cutaneous Squamous Cell Carcinoma |
Intravenous, 1 infusion every 3 weeks |
|
PD-L1 |
Atezolizumab |
NSCLC Urothelial carcinoma TNBC SCLC HCC Melanoma |
Intravenous, 1 infusion every 3 weeks |
|
PD-L1 |
Avelumab |
Merkel cell carcinoma Urothelial carcinoma RCC |
Intravenous, 1 infusion every 2 weeks |
|
PD-L1 |
Durvalumab |
NSCLC SCLC Urothelial carcinoma |
Intravenous, 1 infusion every 2 weeks |
CRC MSI-H: Colorectal cancer microsatellite instability-high; HCC: Hepatocellular carcinoma; HL: Hodgkin lymphoma; NSCLC: Non small cell lung cancer; RCC: Renal cell carcinoma; SCLC: Small cell lung cancer; TNBC: Triple negative breast cancer.